Amendment To Exclusive License Agreement Sample Contracts

Fourth Amendment to Exclusive License Agreement (March 22nd, 2018)

THIS FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Exosomes Fourth Amendment") is made and entered into as of December 26, 2017 ("Fourth Amendment Date") by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation ("CSMC") and CAPRICOR, INC., a Delaware corporation ("Licensee"), under the following circumstances:

Third Amendment to Exclusive License Agreement (March 22nd, 2018)

THIS THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "CDCs Third Amendment") is made and entered into as of December 26, 2017 ("Third Amendment Date") by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation ("CSMC") and CAPRICOR, INC., a Delaware corporation ("Licensee"), under the following circumstances:

Fourth Amendment to Exclusive License Agreement (February 22nd, 2018)

THIS FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Fourth Amendment") is made and entered into as of February 16, 2018 ("Fourth Amendment Date"), by and among CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation ("CSMC"), SYNTHETIC BIOLOGICS, INC., a Nevada corporation ("Synthetic" or "SYN") and SYNTHETIC BIOMICS, INC., a Nevada corporation ("Licensee"), under the following circumstances:

Celyad S.A. – Fourth Amendment to Exclusive License Agreement (August 31st, 2017)

This Fourth Amendment to Exclusive License Agreement (this Amendment) is made and entered into as of this 2nd day of August, 2017 (the Amendment Effective Date), by and among OnCyte, L.L.C., a Delaware limited liability company which is a Subsidiary of Celyad, S.A. (as successor-in-interest to Celdara Medical, LLC) (Company) and Trustees of Dartmouth College, a non-profit educational and research institute existing under the laws of the State of New Hampshire, and being located at Hanover, New Hampshire 03755 (Dartmouth).

First Amendment to Exclusive License Agreement Between the Regents of the University of Michigan and Heat Biologics, Inc. (Um File Number 3680) (March 31st, 2017)

This First Amendment to Exclusive License Agreement (this First Amendment), dated December 1, 2016, is by and between Heat Biologics, Inc. (LICENSEE) and the Regents of the University of Michigan (MICHIGAN).

Aduro BioTech – Second Amendment to Exclusive License Agreement (March 1st, 2017)

This Second Amendment to Exclusive License Agreement (this "Second Amendment") to that certain Exclusive License Agreement for Institutions' Technology "Compositions & Methods for Altering Second Messenger Signaling," effective as of December 18, 2014 (together with all amendments prior the date hereof, the "License Agreement"), by and between Memorial Sloan Kettering Cancer Center, a New York not-for-profit corporation with principal offices at 1275 York Avenue, New York, NY 10065, The Rockefeller University, a New York not-for-profit corporation with principal offices at 1230 York Avenue, New York, NY 10065, Rutgers, The State University of New Jersey, having its statewide Office of Technology Commercialization at 3 Rutgers Plaza, New Brunswick, New Jersey 08901, and University of Bonn, all of which will be collectively referred to as "Institutions" and Aduro Biotech, Inc., a corporation with principal offices located at 626 Bancroft Way, #3C, Berkeley, CA 94710 ("Licensee), is enter

Third Amendment to Exclusive License Agreement (November 14th, 2016)

THIS THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Third Amendment") is made and entered into as of August 5, 2016 ("Amendment Date") by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation ("CSMC") and CAPRICOR, INC., a Delaware corporation ("Licensee"), under the following circumstances:

Threshold Pharmaceuticals – First Amendment to Exclusive License Agreement (May 5th, 2016)

THIS AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT (the "FIRST AMENDMENT") is made and entered into by and between Eleison Pharmaceuticals LLC (as successor to Eleison Pharmaceuticals, Inc.), a Delaware limited liability corporation with a principal place of business at 263 13th Avenue South, Suite 375, St. Petersburg, FL 33701 ("Licensee"), and Threshold Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA ("Licensor") effective January 8, 2016. Licensee and Licensor may each be referred to herein individually as a "Party" and collectively as the "Parties".

Madison Ventures Inc. – Amendment to Exclusive License Agreement Dated August 5, 2015 (March 1st, 2016)
THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 (February 26th, 2016)

This Third Amendment to Exclusive License Agreement ("Third Amendment"), dated as of June 12, 2006, is made by and among The Regents of the University of California, a California corporation ("The Regents"), Medivation, Inc., a Delaware corporation ("Medivation"), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of Medivation ("MPT") (Medivation and MPT together "Licensee").

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 (February 26th, 2016)

This First Amendment to Exclusive License Agreement (this "Amendment"), dated as of November 4, 2005, is made by and among The Regents of the University of California, a California corporation ("The Regents"), Medivation, Inc., a Delaware corporation ("Medivation"), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of Medivation ("MPT")

FIFTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 (February 26th, 2016)

This Fifth Amendment to Exclusive License Agreement ("Fifth Amendment"), dated as of October 21, 2009, is made by and among The Regents of the University of California, a California corporation ("The Regents"), Medivation, Inc., a Delaware corporation ("Medivation"), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of Medivation ("MPT") (Medivation and MPT together "Licensee").

Fourth Amendment to Exclusive License Agreement Between the Regents of the University of California and Medivation, Inc and Medivation Prostate Therapeutics, Inc for UC Agreement Control No. 2006-04-0085 (February 26th, 2016)

This Fourth Amendment to Exclusive License Agreement ("Fourth Amendment"), dated as of July 17, 2007, is made by and among The Regents of the University of California, a California corporation ("The Regents"), Medivation, Inc., a Delaware corporation ("Medivation"), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of Medivation ("MPT") (Medivation and MPT together "Licensee").

SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 (February 26th, 2016)

This Second Amendment to Exclusive License Agreement ("Second Amendment"), dated as of May 8 , 2006, is made by and among The Regents of the University of California, a California corporation ("The Regents"), Medivation, Inc., a Delaware corporation ("Medivation"), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of Medivation ("MPT").

SolarFlex – Amendment to Exclusive License Agreement (January 4th, 2016)

This Amendment to Exclusive License Agreement and Related Instruments, dated as of December 29, 2015 (the "Amendment"), is entered into by and among Solarflex Corp., a Delaware corporation with offices located at 12 Abba Hillel Silver Street, 11th Floor, Ramat Gan 52506, Israel ("Solarflex") and PT Kinerja Indonesia, organized and existing under the laws of Indonesia with offices located at Jl. Multatuli, No.8A, Medan 20151, Indonesia ("PT Kinerja").

Second Amendment to Exclusive License Agreement (November 9th, 2015)

This SECOND Amendment (the "Second Amendment") to the Exclusive License Agreement (JHU Agreement A20530) dated February 16, 2012 and First Amendment (JHU Agreement A24634) dated September 24, 2013 (the Exclusive License Agreement and the First Amendment referred to herein as the "Agreement"), is entered into as of August 7, 2015 ("Amendment Effective Date"), by and among ImmunoCellular Therapeutics Ltd., a Delaware limited liability company having an address at 23622 Calabasas Road, Suite 300, Calabasas, CA 91302 ("COMPANY") and Johns Hopkins University ("JHU"), having offices at 3400 N. Charles Street, Baltimore, MD 21218-2695.

Third Amendment to Exclusive License Agreement (November 5th, 2015)

THIS THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Third Amendment") is made and entered into as of September 4, 2015 ("Third Amendment Date"), by and among CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation ("CSMC"), SYNTHETIC BIOLOGICS, INC., a Nevada corporation ("Synthetic") and SYNTHETIC BIOMICS, INC., a Nevada corporation ("Licensee"), under the following circumstances:

Second Amendment to Exclusive License Agreement (August 14th, 2015)

THIS SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Amendment") is made and entered into as of June 10, 2015 ("Amendment Date"), by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation ("CSMC"), and CAPRICOR, INC., a Delaware corporation ("Licensee"), under the following circumstances:

Islet Sciences, Inc – Fifth Amendment to Exclusive License Agreement (July 7th, 2015)

This FIFTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Fifth Amendment") is dated as of the 6th day of July, 2015 (the "Fifth Amendment Date") by and between Brighthaven Ventures, L.L.C., a North Carolina limited liability company having its registered office at 3200 East Hwy. 54, Suite 100, Research Triangle Park, NC 27709 ("BHV") and Islet Sciences, Inc., a Nevada corporation having its principal place of business at 6601 Six Forks Rd., Suite 140, Raleigh, NC 27615 ("ISLT"). All capitalized terms used in this Fifth Amendment and not otherwise defined herein shall have the meanings set forth in the Agreement.

Islet Sciences, Inc – Fourth Amendment to Exclusive License Agreement (July 1st, 2015)

This FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Fourth Amendment") is dated as of the 29th day of June, 2015 (the "Fourth Amendment Date") by and between Brighthaven Ventures, L.L.C., a North Carolina limited liability company having its registered office at 3200 East Hwy. 54, Suite 100, Research Triangle Park, NC 27709 ("BHV") and Islet Sciences, Inc., a Nevada corporation having its principal place of business at 6601 Six Forks Rd., Suite 140, Raleigh, NC 27615 ("ISLT"). All capitalized terms used in this Fourth Amendment and not otherwise defined herein shall have the meanings set forth in the Agreement.

Islet Sciences, Inc – Third Amendment to Exclusive License Agreement (June 25th, 2015)

This THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Third Amendment") is dated as of the 22nd day of June, 2015 (the "Third Amendment Date") by and between Brighthaven Ventures, L.L.C., a North Carolina limited liability company having its registered office at 3200 East Hwy. 54, Suite 100, Research Triangle Park, NC 27709 ("BHV") and Islet Sciences, Inc., a Nevada corporation having its principal place of business at 6601 Six Forks Rd., Suite 140, Raleigh, NC 27615 ("ISLT"). All capitalized terms used in this Third Amendment and not otherwise defined herein shall have the meanings set forth in the Agreement.

Islet Sciences, Inc – Second Amendment to Exclusive License Agreement (June 15th, 2015)

This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Second Amendment") is dated as of the 14th day of June, 2015 (the "Second Amendment Date") by and between Brighthaven Ventures, L.L.C., a North Carolina limited liability company having its registered office at 3200 East Hwy. 54, Suite 100, Research Triangle Park, NC 27709 ("BHV") and Islet Sciences, Inc., a Nevada corporation having its principal place of business at 6601 Six Forks Rd., Suite 140, Raleigh, NC 27615 ("ISLT"). All capitalized terms used in this Second Amendment and not otherwise defined herein shall have the meanings set forth in the Agreement.

Islet Sciences, Inc – Amendment to Exclusive License Agreement (May 29th, 2015)

This AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Amendment") is dated as of the 29th day of May, 2015 (the "Amendment Date") by and between Brighthaven Ventures, L.L.C., a North Carolina limited liability company having its registered office at 3200 East Hwy. 54, Suite 100, Research Triangle Park, NC 27709 ("BHV") and Islet Sciences, Inc., a Nevada corporation having its principal place of business at 6601 Six Forks Rd., Suite 140, Raleigh, NC 27615 ("ISLT"). All capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings set forth in the Agreement.

First Amendment to Exclusive License Agreement (March 6th, 2015)

THIS FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Amendment") is made and entered into as of February 27, 2015 ("Amendment Date"), by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation ("CSMC"), and CAPRICOR, INC., a Delaware corporation ("Licensee"), under the following circumstances:

FIFTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 (February 25th, 2015)
THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 (February 25th, 2015)

This Third Amendment to Exclusive License Agreement (Thir d Amendment), dated as of June 12, 2006, is made by and among The Regents of the University of California, a California corporation (The Regents), Medivation, Inc., a Delaware corporation (Medivation), and Medivation Prostate Therapeutics, Inc, a Delaware corporation and subsidiary of Medivation (MPT) (Medivation and MPT together Licensee).

Four Th Amendment to Exclusive License Agreement Between the Regents of the University of California and Medivation, Inc and Medivation Prostate Therapeutics, Inc for UC Agreement Control No. 2006-04-0085 (February 25th, 2015)

This Fourth Amendment to Exclusive License Agreement (Fourth Amendment), dated as of July 17, 2007, is made by and among The Regents of the University of California, a California corporation (The Regents), Medivation, Inc , a Delaware corporation (Medivation), and Medivation Prostate Therapeutics, Inc,, a Delaware corporation and subsidiary of Medivation (MPT) (Medivation and MPT together Licensee)

SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 (February 25th, 2015)

California, a California corporation (The Regents), Medivation, Inc , a Delaware corporation (Medivation), and Medivation Prostate Therapeutics, Inc , a Delaware corporation and subsidiary of Medivation (MPT)

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 (February 25th, 2015)

This First Amendment to Exclusive License Agreement (this Amendment), dated as of November 4, 2005, is made by and among The Regents of the University of

Capstone Therapeutics – Second Amendment to Exclusive License Agreement (January 30th, 2015)

This Second Amendment to Exclusive License Agreement (this "Second Amendment") is made effective as of December 15, 2014 (the "Second Amendment Effective Date") by and between The UAB Research Foundation ("UABRF") and LipimetiX Development, LLC ("Licensee"). For purposes of this Second Amendment, each of UABRF and Licensee is referred to herein as a "Party" and collectively, they are referred to as the "Parties".

Zafgen, Inc. – Amendment No. 4 to Exclusive License Agreement (January 12th, 2015)

This Amendment No. 4 to Exclusive License Agreement (this Amendment) is entered into as October 29, 2014, by and between Zafgen, Inc., a Delaware corporation (Zafgen), and Chong Kun Dang Pharmaceutical Corporation, a corporation organized under the laws of the Republic of Korea (CKD), and amends that certain Exclusive License Agreement, dated as of July 6, 2009, by and between Zafgen and CKD, as amended to date (the Agreement). Defined terms used but not otherwise defined herein, shall have the meanings ascribed to such terms in the Agreement.

Amendment No. 1 to Exclusive License Agreement (November 17th, 2014)

This Amendment No. 1 to Exclusive License Agreement (the Amendment No. 1), effective as of September 8, 2014 (the Effective Date), is made by and between Memorial Sloan-Kettering Cancer Center, a New York corporation with principal offices at 1275 York Avenue, New York, New York 10065 (MSKCC), and Juno Therapeutics, Inc., a Delaware corporation having a principal place of business at 307 Westlake Avenue North, Suite 300, Seattle, Washington 98109 (Licensee).

K2M Group Holdings, Inc. – AMENDMENT to EXCLUSIVE LICENSE AGREEMENT (April 7th, 2014)

This Amendment to Exclusive License Agreement, entered into as of the 17th day of February, 2010 (Amendment Effective Date) by and between Spinal LLC (hereafter Spinal), a Florida Limited Liability Company, with its principal place of business located at 360 Tomahawk Drive, Maunee, Ohio 43537, and K2M, Inc., a Delaware Corporation and successor to K2M, LLC (hereafter K2M), with its principal place of business located at 751 Miller Drive, SE, Suite F1, Leesburg, Virginia 20175.

First Amendment to Exclusive License Agreement (March 31st, 2014)

THIS FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Amendment") is made and entered into as of December 13, 2013 ("Effective Date"), by and among CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation ("CSMC"), SYNTHETIC BIOLOGICS, INC., a Nevada corporation, ("Synthetic"), and SYNTHETIC BIOMICS, INC., a Nevada corporation ("Licensee"), under the following circumstances:

Applied Genetic Technologies Corp – SECOND AMENDMENT AFTER RESTATED AMENDMENT to EXCLUSIVE LICENSE AGREEMENT WITH SUBLICENSING TERMS (A2124/Uf#1841) (March 4th, 2014)

This Second Amendment After Restated Amendment to the Exclusive License Agreement With Sublicensing Terms (the Second Amendment) is made as of this 10th day of January 2014 by and among Applied Genetic Technologies Corporation, a Delaware corporation (AGTC) and the University of Florida Research Foundation, Inc., a non-stock, non-profit Florida corporation (UFRF). This Second Amendment amends the Exclusive License Agreement With Sublicensing Terms between AGTC and UFRF (also known as University Agreement No. 2001-09-13B and Agreement A2124/UF#1841), dated September 25, 2001, as amended by (i) the Restated Amendment to License Agreement (B) dated as of January 31, 2005 and (ii) First Amendment After Restated License Agreement (B)(A2124) dated as of November 28. 2007 (as amended, the License Agreement).